rs146733615
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_206933.4(USH2A):c.14803C>T(p.Arg4935Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000291 in 1,613,098 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R4935R) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_206933.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
USH2A | NM_206933.4 | c.14803C>T | p.Arg4935Ter | stop_gained | 68/72 | ENST00000307340.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.14803C>T | p.Arg4935Ter | stop_gained | 68/72 | 1 | NM_206933.4 | P1 | |
USH2A | ENST00000674083.1 | c.14803C>T | p.Arg4935Ter | stop_gained | 68/73 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151226Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251364Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135852
GnomAD4 exome AF: 0.0000308 AC: 45AN: 1461872Hom.: 0 Cov.: 32 AF XY: 0.0000330 AC XY: 24AN XY: 727236
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151226Hom.: 0 Cov.: 31 AF XY: 0.0000136 AC XY: 1AN XY: 73782
ClinVar
Submissions by phenotype
Usher syndrome type 2A Pathogenic:4
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 18, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Genomic Medicine, Manchester, Central Manchester University Hospitals | Feb 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Retinitis pigmentosa 39 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 18, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 13, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 04, 2023 | - - |
Usher syndrome type 2A;C3151138:Retinitis pigmentosa 39 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 16, 2022 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 07, 2023 | This sequence change creates a premature translational stop signal (p.Arg4935*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs146733615, gnomAD 0.003%). This premature translational stop signal has been observed in individuals with Usher syndrome (PMID: 17405132, 29142287). ClinVar contains an entry for this variant (Variation ID: 177760). For these reasons, this variant has been classified as Pathogenic. - |
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 15, 2016 | The p.Arg4935X variant in USH2A has been previously reported in more than nine i ndividuals with either Usher syndrome type II or retinitis pigmentosa (Baux 2007 , Ebermann 2009, Sandberg 2008, McGee 2010, Besnard 2013, LMM data). This varia nt has been also identified in 2/66718 European chromosomes by the Exome Aggrega tion Consortium (http://exac.broadinstitute.org/; dpSNP rs146733615). Although t his variant has been seen in the general population, its frequency is low enough to be consistent with a carrier frequency of a recessive disorder. This nonsens e variant leads to a premature termination codon at position 4935, which is pred icted to lead to a truncated or absent protein. In summary, this variant meets c riteria to be classified as pathogenic for autosomal recessive Usher syndrome. - |
Retinal dystrophy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Jun 15, 2018 | - - |
USH2A-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 08, 2024 | The USH2A c.14803C>T variant is predicted to result in premature protein termination (p.Arg4935*). This variant has been reported many times in individuals with Usher syndrome (see for examples: Baux et al. 2007. PubMed ID: 17405132; Supplemental table, Pierrache et al. 2016. PubMed ID: 26927203; Table S2, Weisschuh et al. 2020. PubMed ID: 32531858). This variant is reported in 0.0026% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in USH2A are expected to be pathogenic. Given the evidence, we interpret this variant as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at